What We're Reading: Page 389
Industry reads hand-picked by our editors
Oct 30, 2014
Oct 29, 2014
-
Pharma Times
Novartis smashes in Q3 as earnings soar 45%
-
-
Roche to spend $3.2B on massive R&D cluster in Basel
-
-
-
-
-
Novartis sells off flu vaccines business to CSL for $275 million
-
Sarepta's mega-orphan Duchenne's drug faces more roadblocks
-
Pfizer pulls the plug on pain deal with Pain Therapeutics
Oct 28, 2014
-
-
Determined Shire ratchets up 2014 forecast, again
-
-
Merck beats Q3 forecasts, scores another Keytruda 'breakthrough'
-
-
FDA approves Baxter's hemophilia orphan drug
-
The 14 best-performing CEOs in biotech and pharma
-
EMA recommends approval of AZ's ovarian cancer drug
-
-
Valeant poised to raise Allergan bid
Oct 27, 2014
-
-
EU reverses course, won't cede drug-related decisions to pharma
-
BMS beats analyst expectations on strong cancer, RA drug sales
-
-
-
-
-
-
EMA establishes expedited review framework for Ebola vaccines
-
Soliris sales drive Alexion's Q3 earnings beyond the loftiest expectations
Oct 24, 2014
-
-
Anti-inflammatories may boost the effects of antidepressants
-
-
Lilly's Q3 profits drop sharply, hammered by patent expirations
-
WHO decries funding gap for tuberculosis R&D
-
-
Biogen shares down as Tecfidera-treated patient dies from viral brain infection
-
-
-
Oct 23, 2014
-
Best of BD: Is the current antibiotic pipeline really that bad? [INFOGRAPHIC]
-
Glaxo, Abbott Q3 earnings best analyst expectations
-
-
-
-
-
Study: Parkinson's disease drugs make some patients want to party
-
-
Mylan investor pulls $70 million as lethal injection controvery heats up
-
How the FDA plans to stop facilities from undermining inspections
-
Lilly, Boehringer fixed-dose diabetes combo could win FDA blessing soon
Oct 22, 2014
-
Useful insights: Europe slow to embrace biosimilars of antibody-based drugs
-
-
-
-
Study: Viagra could be used to protect against heart disease
-
-
-
PhRMA fights back, blames insurance companies for drug access woes
-
Genentech strikes rare $1.15B cancer pact with NewLink Genetics
-
Actelion chief says it's time for pharma to ditch tax-inversion mergers
Previous
